Post Learning Implementation Plan (PLIP)

Pre-course

• Access to the Educo Training Portal
• Submit your needs analysis and objectives for training by completing a simple online form

Action Plan

• At the end of the training you will create an action plan to help you implement and develop your new skills and knowledge

Reinforcement Session

• Delivered 3 to 4 weeks after the training
• It is a 1 hour virtual session enabling the group to reinforce the key learnings from the training and cover subsequent questions and challenges

w/c 1 December 2025 | w/c 1 June 2026 | w/c 30 November 2026

1 Week Live Online Training

Register at the top of the page. The largest price saving of £400 will be applied.

Introductory Online Module

FREE to Attend | Live & Recorded

10 September 2025 | 60 mins | 1:00 PM UK

Delivered Online

Overview of assays in biologics

During the first session we will explore the special nature of biologics and what makes them so complex. We will walk through the fundamentals of the clinical and manufacturing related assays we need to set up to ensure safety & efficacy of our biologics

• Large versus small molecules
• Clinical assessment of efficacy and safety
  • Fundamentals of PK/PD/Immunogenicity assays
• Manufacturing of clinical batches
  • Fundamentals of potency assays

Register For Online Session | Free

There are limited spaces on the introductory session. If demand is high you may not be able to attend the live session, however you will be sent the recording. Priority is given to full registrations.

Session 1

1 December 2025 | 180 mins | 1:00 PM (UK time)

 Quality by Design (QbD) and the Assay Life cycle of a potency assay

• What is Quality by Design?
• How does it apply to assays?
• What is potency?
• The importance of Mode of Action
• Ligand binding vs cell-based assays

The quality system

• Qualification vs validation
• The GxP system
• Guidelines
• The QC system

Session 2

2 December 2025 | 120 mins | 1:00 PM (UK time)

Phase appropriate validation

• Phase I assays
• Phase II assays
• Phase III assays

Practical exercises, group work and case studies

Interactive group exercises in the form of discussion and/or exercises are also included as part of the course to cement your knowledge.

Session 3

3 December 2025 | 120 mins | 1:00 PM (UK time)

Reference material

• Phase-appropriate use of reference material
• Change of reference material – bridging
• Influence of excipients/formulation

Session 4

4 December 2025 | 120 mins | 1:00 PM (UK time)

Design of Experiments (DoE)

• What is DoE? The origin
• How can DoE be applied to an assay?
• Screening vs optimization
• Case Studies

Session 5

5 December 2025 | 120 mins | 1:00 PM (UK time)

The curious case of cell & gene therapy products

• What is so special about CGT and potency?
• Alternative technologies such as flow cytometry
• Latest guidance in CGT and potency

Practical exercises, group work and case studies

Interactive group exercises in the form of discussion and/or exercises are also included as part of the course to cement your knowledge.

Dr. Melody Janssen is an expert in bioanalysis and immunogenicity testing of biopharmaceuticals with in-depth experience as a project manager, trainer and senior expert in CROs and pharma/biotech companies. She worked predominantly on developing and validating ligand-binding and cell-based assays for PK/Tox and immunogenicity studies for biologics, biosimilars and vaccines and her work supported numerous regulatory filings. Dr. Janssen is experienced in the regulatory framework related to bioanalytical method establishment and validation including FDA, EMA, ICH guidelines and USP and Ph.Eur. monographs. She is frequently invited to speak at conferences on immunogenicity and bioanalytical testing, where she also leads conference specific workshops and seminars. She has shared her knowledge through trainings for over 10 years focusing on assay validation for bioanalytical, potency and immunogenicity assays. Recently she became a regular evaluator for the Swedish innovation agency, Vinnova, where her task is to assess the scientific rational and business proposals of start-up biotech companies competing for seed funding.

Based on her role as the head of non-clinical development at Mymetics, a viral vaccine company, she has gained experience on aspects related to the production of biologics and vaccines, potency assays and GMP.

For the last years, Dr. Janssen has been working as a freelancer for projects including non-clinical and clinical immunogenicity assessment, leading various late pre-clinical candidates to FIH, production of vaccines and biologics and teaching bioanalytical method validation workshops.

Her educational background is in infectious diseases and immunology, with a PhD in pharmaceutical sciences investigating the effect of protein aggregates on immunogenicity.